To assess whether the combination of cetuximab and pembrolizumab (Arm 2) compared to pembrolizumab alone (Arm 1)
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Sid Sheth
LCCC - Clinical Trials
Clinical or Medical
Interventional
Cancer (Head and Neck)
24-3056
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
